Mylan Inc (MYL.OQ)
34.05USD
1 Aug 2013
$0.49 (+1.46%)
$33.56
$33.73
$34.62
$33.73
157,779
1,206,224
$34.62
$22.51
About
Overall
| Beta: | 0.78 |
| Market Cap (Mil.): | $12,789.37 |
| Shares Outstanding (Mil.): | 381.09 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MYL.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 22.46 | 37.93 | 37.76 |
| EPS (TTM): | 1.49 | -- | -- |
| ROI: | 6.40 | 19.48 | 18.76 |
| ROE: | 18.54 | 20.17 | 19.59 |
Mylan earnings rise, but dollar drags on revenue
- Mylan Inc's quarterly earnings rose 28 percent, but the generic drugmaker said the weakness of the Indian and Japanese currencies against the dollar would put 2013 revenue at the low end of its forecast range of $7 billion to $7.4 billion.
UPDATE 1-Mylan earnings rise, but dollar drags on revenue
Aug 1 - Mylan Inc's quarterly earnings rose 28 percent, but the generic drugmaker said the weakness of the Indian and Japanese currencies against the dollar would put 2013 revenue at the low end of its forecast range of $7 billion to $7.4 billion.
Mylan second quarter earnings rise, but foreign exchange drags
Aug 1 - Generic drugmaker Mylan Inc said on Thursday that its second-quarter earnings rose, but forecast 2013 revenue would be at the low end of an expected $7 billion to $7.4 billion range because of the weakening of India's and Japan's currencies against the dollar.
Mylan says court dismisses some of Teva's patent claims on MS drug
- A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.
Mylan says court dismisses some of Teva's patent claims on MS drug
July 16 - A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.
DEALTALK: Game may not be over for Royalty' Pharma's bid for Elan
NEW YORK, June 27 - The game may not yet be over for U.S investment firm Royalty Pharma in its months-long pursuit of Elan Corp.
Warner Chilcott buy may be Actavis' best takeover defense
NEW YORK - Generic drugmaker Actavis , the subject of intense takeover speculation, may have found its best defense: a potential purchase of Warner Chilcott Plc , a specialty pharmaceutical company that has been for sale on and off for years.
Market Chatter-Corporate finance press digest
May 15 - The following corporate finance-related stories were reported by media on Wednesday:
Actavis rejected $15 billion offer from Mylan: source
NEW YORK - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.
Actavis rejected $15 billion offer from Mylan - source
NEW YORK, May 14 - Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.
Competitors
| Price | Change | |
|---|---|---|
| Dr. Reddy's Laboratories Limited (REDY.NS) | Rs2,278.45 | -2.75 |
| Johnson & Johnson (JNJ.N) | $94.04 | +0.54 |
| Pfizer Inc. (PFE.N) | $29.29 | +0.06 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.34 | +0.17 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Abbott Laboratories (ABT.N) | $36.73 | +0.10 |
| Bayer AG (BAYGn.DE) | €89.64 | +2.29 |
| Bayer AG (BAYE.F) | -- | -- |
| GlaxoSmithKline plc (GSK.L) | 1,702.36p | +18.50 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (MYL). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

